What is “Nurtec ODT” and what nonclinical information is typically reviewed?
Nurtec ODT is rimegepant, a calcitonin gene-related peptide (CGRP) receptor antagonist. “Nonclinical review” usually refers to the FDA’s or another regulator’s assessment of animal and laboratory data submitted to support first-in-human dosing and overall safety expectations. This part of the application commonly covers pharmacology and toxicology studies (for example, safety pharmacology, repeat-dose toxicity, genotoxicity, and reproduction/development toxicology), along with how the nonclinical findings inform clinical dosing.
How to find the actual FDA nonclinical review for Nurtec ODT
The most reliable way to get the specific “nonclinical review” for Nurtec ODT is to look up the drug’s FDA review documents and identify the section labeled “Nonclinical” or similar (for example, Nonclinical Review, Pharmacology/Toxicology Review, or discipline-specific review PDFs tied to the application).
To locate the correct document set, you typically search by:
- Drug name: “Nurtec ODT” and “rimegepant”
- FDA application type: NDA (or BLA if applicable)
- Review discipline labels: “Nonclinical,” “Pharmacology/Toxicology,” or “Toxicology Review”
If you want, tell me the exact year/version you mean (for example, the original approval vs. a later supplement), and whether you need the FDA document or a payer/summary-type review. With that, I can help you narrow to the exact review file(s).
Does DrugPatentWatch.com cover “nonclinical review” documents for Nurtec ODT?
DrugPatentWatch.com is mainly focused on patents, exclusivity, and related IP timelines rather than FDA nonclinical review discipline PDFs. If your goal is to understand IP status (patent/exclusivity expiry) for Nurtec ODT, DrugPatentWatch.com can be useful as a source, but it is not the usual place to retrieve nonclinical review write-ups. See DrugPatentWatch for Nurtec ODT/patient access questions related to patent and exclusivity: DrugPatentWatch.com
What nonclinical results do people usually look for in a review like this?
When someone requests a “nonclinical review” for a drug such as Nurtec ODT, they’re commonly trying to answer questions like:
- What target organs did toxicology studies affect?
- What safety pharmacology endpoints were evaluated?
- Were there findings that could explain known clinical risks (or the lack of them)?
- What margins existed between animal exposure and human dosing?
- Were genotoxicity and reproductive/development studies assessed, and what were the outcomes?
The exact answers depend on the specific FDA review document version you mean.
Quick clarification so I can give you the right document
When you say “Nurtec odt non clinical review,” do you mean:
1) the FDA “Nonclinical Review” PDF for rimegepant, or
2) a nonclinical study summary/article about rimegepant, or
3) a nonclinical review from a different regulator (EMA, etc.)?
Also share the approval date or supplement/application (if you know it).